论文部分内容阅读
目的观察紫杉醇联合吡柔比星化疗治疗晚期乳腺癌的疗效和毒副作用。方法乳腺癌患者16例,治疗第1天紫杉醇135mg/m2静脉滴注,第2天吡柔比星40mg/m2静脉注射,28d为1治疗周期,2周期后参照WHO实体瘤评价标准进行评价。结果完全缓解(CR)2例,部分缓解(PR)9例,稳定(SD)3例,进展(PD)2例,总有效率68.8%(11/16),初治有效率为83.3%(5/6)。毒副反应主要为骨髓抑制、中性粒细胞减少。结论紫杉醇联合吡柔比星化疗可以提高晚期乳腺癌的疗效,毒副反应可以耐受。
Objective To observe the efficacy and toxicity of paclitaxel combined with pirarubicin in the treatment of advanced breast cancer. Methods Sixteen patients with breast cancer were treated with intravenous 135 mg/m2 paclitaxel on the first day of treatment, 40 mg/m2 intravenously with pirarubicin on the second day, and 1 treatment cycle on 28 days. After 2 cycles, they were evaluated according to WHO solid tumor evaluation criteria. Results There were 2 cases of complete remission (CR), 9 cases of partial remission (PR), 3 cases of stable (SD), 2 cases of progressive (PD). The total effective rate was 68.8% (11/16), and the initial effective rate was 83.3% ( 5/6). The toxic side effects were mainly myelosuppression and neutropenia. Conclusion Paclitaxel combined with pirarubicin can improve the efficacy of advanced breast cancer, and the toxicity can be tolerated.